

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
28 December 2016**

**ORDER GRANTING CONFIDENTIAL TREATMENT
UNDER THE SECURITIES ACT OF 1933 AND
THE SECURITIES EXCHANGE ACT OF 1934**

Genocea Biosciences, Inc.

File Nos. 333-193043 and 1-36289 -- CF# 34308

Genocea Biosciences, Inc. submitted an application under Rules 406 and 24b-2 requesting an extension of a previous grant of confidential treatment for information it excluded from (i) Exhibits 10.2 and 10.3 to Form S-1 filed on December 23, 2013, as amended, as modified by the same contract refiled with fewer redactions as Exhibits 10.1 and 10.2 to a Form 10-Q filed on November 4, 2016, (ii) Exhibit 10.4 to Form S-1 filed on December 23, 2013, as amended, as modified by the contract filed with fewer redactions and additional text as Exhibit 10.3 to a Form 10-Q filed on November 4, 2016, and (iii) Exhibit 10.5 to Form S-1 filed on December 23, 2013, as amended, and refiled as Exhibit 10.4 to a Form 10-Q filed on November 4, 2016.

Based on representations by Genocea Biosciences, Inc. that this information qualifies as confidential commercial or financial information under the Freedom of Information Act, 5 U.S.C. 552(b)(4), the Division of Corporation Finance has determined not to publicly disclose it. Accordingly, excluded information from the following exhibit(s) will not be released to the public for the time period(s) specified:

| Exhibit | To Form | Filed on | Confidential Treatment Granted |
|----------------|----------------|-------------------|---------------------------------------|
| 10.2 | S-1 | December 23, 2013 | through October 22, 2019 |
| 10.3 | S-1 | December 23, 2013 | through October 22, 2019 |
| 10.4 | S-1 | December 23, 2013 | through October 22, 2019 |
| 10.5 | S-1 | December 23, 2013 | through October 22, 2019 |
| 10.1 | 10-Q | November 4, 2016 | through October 22, 2019 |
| 10.2 | 10-Q | November 4, 2016 | through October 22, 2019 |
| 10.3 | 10-Q | November 4, 2016 | through October 22, 2019 |
| 10.4 | 10-Q | November 4, 2016 | through October 22, 2019 |

For the Commission, by the Division of Corporation Finance, pursuant to delegated authority:

Brent J. Fields
Secretary